Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avelumab - Merck KGaA

Drug Profile

Avelumab - Merck KGaA

Alternative Names: Anti-CD274-monoclonal-antibody; Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck KGaA; BAVENCIO; MSB-0010718C; PF-06834635

Latest Information Update: 24 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck KGaA
  • Developer AIO Studien gGmbH; Array BioPharma; Chong Kun Dang; Dana-Farber Cancer Institute; Debiopharm; eFFECTOR Therapeutics; EMD Serono; Forty Seven; Fred Hutchinson Cancer Research Center; Gachon University Gil Medical Center; Hellenic Cooperative Oncology Group; Hoosier Cancer Research Network; Hospices Civils de Lyon; Istituto Oncologico Veneto; Johannes Gutenberg-University Mainz; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); National Cancer Institute Slovakia; Netherlands Cancer Institute; Pfizer; Seoul National University Hospital; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Transgene; University College London; University of Birmingham; University of California, San Diego; University of Iowa; University of North Carolina at Chapel Hill; University of Padua; Vaccinex; Vanderbilt-Ingram Cancer Center; VAXIMM; Verastem Oncology; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Merkel cell carcinoma; Renal cell carcinoma; Urogenital cancer
  • Phase III Breast cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Phase II Bladder cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Gestational trophoblastic disease; Glioblastoma; Haemangiosarcoma; Hodgkin's disease; Intestinal cancer; Leiomyosarcoma; Liver cancer; Lymphoma; Malignant thymoma; Nasopharyngeal cancer; Neuroendocrine tumours; Oesophageal cancer; Osteosarcoma; Penile cancer; Peripheral T-cell lymphoma; Peritoneal cancer; Prostate cancer; Recurrent respiratory papillomatosis; Small cell lung cancer; Squamous cell cancer; Thymoma
  • Phase I/II Anal cancer; Bone metastases; Cervical cancer; Liposarcoma; Oropharyngeal cancer; Pancreatic cancer; Vulvovaginal cancer
  • Phase I Acute myeloid leukaemia; Follicular lymphoma; Meningioma

Most Recent Events

  • 19 May 2021 Updated efficacy data from Part A of the phase II JAVELIN Merkel 200 trial in Merkel cell carcinoma released by EMD Serono
  • 06 May 2021 NICE does not recommend avelumab for maintenance treatment of advanced or metastatic Urogenital cancer after platinum-based chemotherapy in its draft guidance
  • 03 May 2021 Pfizer and University of California, San Diego terminates a phase I/II clinical trial in Non-small cell lung cancer (Early-stage disease, Inoperable/Unresectable) in USA (IV) (NCT03050554)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top